Updates

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com www.biocon.com BIO/SECL/TG/2026-27/73 October 14, 2026 To To The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Subject: Company Statement Dear Sir/Madam, Please find enclosed Company Statement w.r.t. “Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech”. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 Encl: Company Statement NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech BENGALURU, India: October 14, 2026 Biocon Limited (BSE: 532523, NSE: BIOCON) has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch dates for Pebrilzo®, its biosimilar to the reference product Perjeta® (Pertuzumab). Biocon and Genentech executed the patent settlement agreement to resolve all pending disputes between the companies, including in the U.S., Canada, and other jurisdictions. This global patent settlement and license agreement enables Biocon to launch Pebrilzo® in Q1 of calendar year (CY) 2027 in the European Union and UK, Q3 of CY 2028 in the U.S., and in CY 2026-2028 in other Rest of the World (RoW) countries or earlier in certain circumstances. The other terms of the agreement are confidential. Pebrilzo® is a biosimilar medicinal product and the active substance is Pertuzumab, a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2. Pebrilzo® is used for the treatment of HER2-positive breast cancer across multiple disease stages. Note: • All trademarks, registered or unregistered, are the property of their respective owners. • Product launches in all the countries/ regions are subject to regulatory approval. Forward-Looking Statement: Statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.